LivaNova (NASDAQ:LIVN) Stock Rating Lowered by StockNews.com

LivaNova (NASDAQ:LIVN - Get Free Report) was downgraded by investment analysts at StockNews.com from a "strong-buy" rating to a "buy" rating in a research report issued on Thursday.

Other equities research analysts have also recently issued research reports about the stock. Mizuho lowered their price target on shares of LivaNova from $80.00 to $70.00 and set an "outperform" rating for the company in a research report on Thursday, October 31st. Needham & Company LLC reiterated a "buy" rating and issued a $75.00 price objective on shares of LivaNova in a research report on Monday, November 25th. The Goldman Sachs Group initiated coverage on shares of LivaNova in a report on Friday, October 4th. They issued a "buy" rating and a $65.00 price target for the company. Finally, Robert W. Baird raised their price objective on shares of LivaNova from $66.00 to $72.00 and gave the stock an "outperform" rating in a report on Thursday, October 31st. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $69.17.

LivaNova Price Performance

Shares of NASDAQ LIVN traded up $0.17 during trading on Thursday, reaching $48.82. The company had a trading volume of 486,916 shares, compared to its average volume of 456,844. LivaNova has a 52 week low of $43.15 and a 52 week high of $64.47. The business's 50 day moving average price is $49.26 and its 200-day moving average price is $50.02. The stock has a market cap of $2.65 billion, a PE ratio of 116.24 and a beta of 1.01. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37.

Insider Activity

In related news, Director Francesco Bianchi sold 1,250 shares of the stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total transaction of $63,737.50. Following the sale, the director now owns 7,522 shares of the company's stock, valued at $383,546.78. This represents a 14.25 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.27% of the stock is owned by company insiders.

Institutional Investors Weigh In On LivaNova

Several institutional investors and hedge funds have recently added to or reduced their stakes in LIVN. Nordea Investment Management AB raised its holdings in shares of LivaNova by 22.2% during the 4th quarter. Nordea Investment Management AB now owns 68,711 shares of the company's stock worth $3,188,000 after buying an additional 12,470 shares in the last quarter. Driehaus Capital Management LLC boosted its stake in shares of LivaNova by 64.7% in the 2nd quarter. Driehaus Capital Management LLC now owns 544,042 shares of the company's stock valued at $29,824,000 after purchasing an additional 213,749 shares in the last quarter. Harbor Capital Advisors Inc. bought a new stake in shares of LivaNova during the 4th quarter valued at approximately $1,954,000. Perceptive Advisors LLC increased its position in LivaNova by 48.5% during the 2nd quarter. Perceptive Advisors LLC now owns 444,000 shares of the company's stock worth $24,340,000 after purchasing an additional 145,000 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its stake in LivaNova by 3.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 797,284 shares of the company's stock valued at $41,889,000 after purchasing an additional 25,277 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.